{'fraction_non_alphanumeric': 0.027463651050080775, 'fraction_numerical': 0.021809369951534735, 'mean_word_length': 4.816901408450704, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Percutaneous nephrostomy in patients with advanced or recurrent cervical cancer.

Thirteen percutaneous nephrostomies were performed in 10 patients with advanced (no = 4) (group A) or recurrent (no = 6) (group B) cervical cancer. Urinary diversion was unilateral in 7 patients and bilateral in 3 patients. The catheter was kept in place for 4 months in mean (range: 1-7 months). A normalization of renal function was achieved in 4 out of 4 patients of group A, and in 3 out of 6 patients of group B. Of the 4 patients of group A, who afterwards underwent antineoplastic integrated treatments, 2 patients are currently alive with no evidence of disease after 48 and 20 months from the diagnosis, respectively, while the other 2 died of disease after 10 and 14 months, respectively. Of the 6 patients of group B, 5 patients died within 7 months, while another patient is currently undergoing chemotherapy. The present data seem to confirm that percutaneous nephrostomy can be of clinical benefit for patients with advanced cervical cancer, having a chance of prolonged palliation or cure. Conversely, this technique seems to be of little use for patients with recurrent disease, for whom no effective salvage therapy is generally available.